The NCI Board of Scientific Advisors approved 10 concepts, including eight new concepts and two re-issued Requests for Applications in a joint meeting with the National Cancer Advisory Board on June 26 and 27.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
